MAPT and Alzheimer disease: To evaluate the different levels and distributions of MSI1 and MSI2 amongst varying neurodegenerative diseases, we co-stained AD, ALS, FTD, aged Control brains MSI1 (Fig. 1g) and MSI2 (Fig. 1h) with anti-tau oligomeric monoclonal antibody (TOMA-2).